Rodriguez J.,University Hospital Severo Ochoa |
Gutierrez A.,Service of Hematology |
Obrador-Hevia A.,Cancer Cell Biology Group |
Fernandez De Mattos S.,Cancer Cell Biology Group |
Cabanillas F.,University of Puerto Rico at San Juan
European Journal of Haematology | Year: 2010
Mantle cell lymphoma has been considered an incurable disease with current chemotherapy regimens. Recent intense chemoimmunotherapy induction regimens with or without consolidation with autologous stem cell transplantation procedures are showing a potential for cure in a sizable fraction of patients. Similarly, in the salvage setting, preliminary experience with non-myeloablative allogeneic transplant may cure some patients even after multiple therapeutic failures. However, the recent knowledge of the three basic biologic derangements that are integrated in the disease may change the therapeutic approach of the disease in the near future. In fact, new drugs that target more specifically the major molecular alterations of the disease are being progressively incorporated into the therapeutic armamentarium of the disease. In the near future, more individualized approaches that will take into account not only risk factors present at diagnosis but also biomarkers representative of the molecular alterations present in the disease are foreseen. In this review, we are going to discuss the current therapeutic approaches and the main new drugs that target more specifically the major molecular pathways alterations of the disease. © 2010 John Wiley & Sons A/S.